Posted by Administrator on May 9th, 2006 — in Nexium Top News
WILMINGTON, Del., May 1 /PRNewswire-FirstCall/ — AstraZeneca (NYSE:AZN) announced today that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM(R) (esomeprazole magnesium) delayed release capsules, in children ages 12 to 17 for the short-term treatment of gastroesophageal reflux disease (GERD).
“GERD isn’t just a disease that affects adults, it also is common […]
No Comments »
Posted by Administrator on May 9th, 2006 — in Nexium Top News
Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced positive results from a recently completed clinical study that evaluated ZEGERID(R) (omeprazole/sodium bicarbonate) Powder for Oral Suspension 40 mg/1680 mg, Nexium(R) (esomeprazole magnesium) delayed-release capsules 40 mg and Prevacid(R) (lansoprazole) delayed-release capsules 30 mg with regard to reducing […]
No Comments »